Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Achillion Pharmaceuticals has commenced patient dosing in its segment 2 a double-blind, randomized Phase 2a trial to evaluate ACH-1625 as treatment of hepatitis C virus (HCV) for genotype 1 treatment naive HCV-infected patients.
Subscribe to our email newsletter
The company expects to assess the antiviral activity, tolerability and safety of ACH-1625 in conjunction with standard of care (SOC) consisting of pegylated interferon alfa-2a and ribavirin.
In the trial, the patients will be randomized to be given once daily doses of 200mg, 400mg or 800mg of ACH-1625 in conjunction with SOC for 12 weeks of dosing.
In previous trials ACH-1625 has demonstrated low single-digit nanomolar potency that is specific to HCV.
Achillion vice president and chief medical officer Elizabeth Olek said initiating the second segment of this Phase 2 clinical trial allows them to build upon the robust RVR results they observed with ACH-1625, and to further augment the safety and efficacy database by taking the opportunity to study multiple doses of ACH-1625.